Hello, everyone, and how are you this morning? We are doing just fine, thank you, now that the Pharmalot campus has quieted down. The short person has left for the local summer job and, as always, the official mascots are snoozing here and there. We, however, have no time to nap, since there is always much to be done. The world, after all, continues to spin no matter what. On that note, here are a few items of interest. Hope your day goes well and that you will reach out if anything interesting arises …

Novartis (NVS) is closing its antibiotic and antiviral research operations in the San Francisco Bay area and cutting about 140 jobs, the latest big drug maker to abandon this field. The company, which is not abandoning research into tropical diseases such as malaria, is looking to license its early-stage products and stressed that its Sandoz generics unit continues to manufacture and sell antibiotics and antivirals. The Access to Medicines Foundation noted that Novartis had 32 antimicrobial research and development projects in its pipeline.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy